Laimoud MH, Raslan IR. Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure. World J Cardiol 2024; 16(11): 665-668 [DOI: 10.4330/wjc.v16.i11.665]
Corresponding Author of This Article
Mohamed H Laimoud, MD, PhD, Associate Professor, Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Makkah Al Mukarramah Br Road, As Sulimaniyah, Riyadh, Riyadh 12611, Saudi Arabia. m.laimoud@cu.edu.eg
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Nov 26, 2024; 16(11): 665-668 Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.665
Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure
Mohamed H Laimoud, Ismail R Raslan
Mohamed H Laimoud, Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Riyadh 12611, Saudi Arabia
Mohamed H Laimoud, Critical Care Medicine, Cairo University, Cairo 12613, Egypt
Ismail R Raslan, Department of Cardiac Sciences, King Saud University, Riyadh 11362, Saudi Arabia
Ismail R Raslan, Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh 12611, Saudi Arabia
Author contributions: Laimoud MH and Raslan IR contributed equally to this editorial manuscript and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohamed H Laimoud, MD, PhD, Associate Professor, Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Makkah Al Mukarramah Br Road, As Sulimaniyah, Riyadh, Riyadh 12611, Saudi Arabia. m.laimoud@cu.edu.eg
Received: August 24, 2024 Revised: October 14, 2024 Accepted: October 23, 2024 Published online: November 26, 2024 Processing time: 67 Days and 10.7 Hours
Abstract
Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have been increasingly used with proven efficacy in patients with heart failure (HF), regardless of diabetes status. Grubić Rotkvić et al recently published an observational study on SGLT2i therapy in patients with type 2 diabetes mellitus and asymptomatic HF. They found that the use of SGLT2i led to reduced cardiac load and improved cardiovascular performance, reinforcing the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with type 2 diabetes mellitus. The study by Grubić Rotkvić et al contributes to the growing body of literature supporting the early use of SGLT2i in patients with diabetic cardiomyopathy, offering a potential strategy to mitigate the progression of HF. Future larger studies should be conducted to confirm these findings, and explore the long-term cardiovascular benefits of SGLT2i, particularly in asymptomatic patients at risk of developing HF.
Core Tip: Grubić Rotkvić et al published an observational study on the use of sodium-dependent glucose transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus and asymptomatic heart failure. Their findings included reduced cardiac load and improved cardiovascular performance related to the use of SGLT2i. This suggests that SGLT2i are not merely glucose-lowering drugs; they are integral to the broader cardiovascular management in patients with type 2 diabetes mellitus.
